Selumetinib

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 783 publications

Correction to: Real-world outcomes for selumetinib in pediatric patients with neurofibromatosis type 1 and plexiform neurofibromas in Japan: A 1-year interim analysis.

Correction to: Real-world outcomes for selumetinib in pediatric patients with neurofibromatosis type 1 and plexiform neurofibromas in Japan: A 1-year interim analysis.

Journal: Neuro-oncology advances

Published: August 28, 2026

Latest Classification and Management of Circumscribed Astrocytic Gliomas

Latest Classification and Management of Circumscribed Astrocytic Gliomas

Journal: No shinkei geka. Neurological surgery

Published: August 16, 2026

Drug-induced paronychia: a disproportionality and time-to-onset pharmacovigilance study using FAERS and JADER.

Drug-induced paronychia: a disproportionality and time-to-onset pharmacovigilance study using FAERS and JADER.

Journal: Cutaneous and ocular toxicology

Published: July 07, 2026

Combinatorial Targeting of Avapritinib-Driven MAP Kinase Activation in High-Grade Glioma.

Combinatorial Targeting of Avapritinib-Driven MAP Kinase Activation in High-Grade Glioma.

Journal: Research square

Published: July 03, 2026

Combinatorial Targeting of Avapritinib-Driven MAP Kinase Activation in High-Grade Glioma.

Combinatorial Targeting of Avapritinib-Driven MAP Kinase Activation in High-Grade Glioma.

Journal: Research square

Published: July 03, 2026

Efficacy of redifferentiation therapy in radioactive iodine refractory thyroid cancer: a systematic review and meta-analysis.

Efficacy of redifferentiation therapy in radioactive iodine refractory thyroid cancer: a systematic review and meta-analysis.

Journal: European journal of nuclear medicine and molecular imaging

Published: June 05, 2026

Atypical Neurofibromatous Neoplasms of Uncertain Biological Potential in Children with Neurofibromatosis Type 1: Report of Two Patients and Review.

Atypical Neurofibromatous Neoplasms of Uncertain Biological Potential in Children with Neurofibromatosis Type 1: Report of Two Patients and Review.

Journal: International journal of surgical pathology

Published: May 14, 2026

MEK inhibitors for neurofibromatosis type 1-associated central and peripheral nervous system tumors.

MEK inhibitors for neurofibromatosis type 1-associated central and peripheral nervous system tumors.

Journal: Neuro-oncology advances

Published: April 30, 2026

Risk of developing malignant peripheral nerve sheath tumors in patients with neurofibromatosis 1 receiving MEK inhibitor treatment for plexiform neurofibromas.

Risk of developing malignant peripheral nerve sheath tumors in patients with neurofibromatosis 1 receiving MEK inhibitor treatment for plexiform neurofibromas.

Journal: Neuro-oncology advances

Published: April 28, 2026

Malignant peripheral nerve sheath tumor development during MEK inhibitor treatment: A pre-clinical study and a clinical case series.

Malignant peripheral nerve sheath tumor development during MEK inhibitor treatment: A pre-clinical study and a clinical case series.

Journal: Neuro-oncology advances

Published: April 27, 2026

Using Patient iPSC-derived Retinal Pigment Epithelial Cells to Evaluate Differential Susceptibility to MEK Inhibitor-Associated Retinopathy.

Using Patient iPSC-derived Retinal Pigment Epithelial Cells to Evaluate Differential Susceptibility to MEK Inhibitor-Associated Retinopathy.

Journal: bioRxiv : the preprint server for biology

Published: April 27, 2026

TEAD inhibitors re-sensitize drug-resistant NF1 MPNST cells to MEK inhibitors.

TEAD inhibitors re-sensitize drug-resistant NF1 MPNST cells to MEK inhibitors.

Journal: microPublication biology

Published: April 22, 2026

Showing 1-12 of 783

Last Updated: 09/26/2026